MX2021001039A - Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas. - Google Patents
Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas.Info
- Publication number
- MX2021001039A MX2021001039A MX2021001039A MX2021001039A MX2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A
- Authority
- MX
- Mexico
- Prior art keywords
- patients
- stem cell
- hematopoietic stem
- cell transplantation
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018141411 | 2018-07-27 | ||
| JP2019036598 | 2019-02-28 | ||
| PCT/JP2019/029524 WO2020022507A1 (ja) | 2018-07-27 | 2019-07-26 | 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001039A true MX2021001039A (es) | 2021-04-12 |
Family
ID=69181631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001039A MX2021001039A (es) | 2018-07-27 | 2019-07-26 | Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210283073A1 (https=) |
| EP (1) | EP3831370A4 (https=) |
| JP (1) | JP7389486B2 (https=) |
| KR (1) | KR102948053B1 (https=) |
| CN (2) | CN112512516A (https=) |
| AU (1) | AU2019311609B2 (https=) |
| BR (1) | BR112021001376A2 (https=) |
| IL (1) | IL280451B2 (https=) |
| MX (1) | MX2021001039A (https=) |
| TW (1) | TWI899057B (https=) |
| WO (1) | WO2020022507A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021424131A1 (en) * | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
| EP4248958A3 (en) | 2021-01-28 | 2024-01-03 | Priothera SAS | Methods of treatment with s1p receptor modulators |
| EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1431275B1 (en) | 2001-09-27 | 2010-04-07 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| MXPA04002679A (es) | 2001-09-27 | 2004-07-30 | Kyorin Seiyaku Kk | Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos. |
| CN101014329B (zh) * | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| EP1806338B1 (en) | 2004-10-12 | 2016-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof |
| SI1932522T1 (sl) | 2005-10-07 | 2012-08-31 | Kyorin Seiyaku Kk | Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| AU2009206733A1 (en) * | 2008-01-25 | 2009-07-30 | Arena Pharmaceuticals, Inc. | Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists |
| WO2014120949A1 (en) * | 2013-01-30 | 2014-08-07 | Memorial Sloan-Kettering Cancer Center | Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation |
| US20160000811A1 (en) * | 2013-02-20 | 2016-01-07 | Novartis Ag | Treatment of graft versus host disease in transplant patients |
| US10154989B2 (en) * | 2015-09-17 | 2018-12-18 | Emory University | Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof |
| WO2017153889A1 (en) | 2016-03-08 | 2017-09-14 | Novartis Ag | Treatment of hematopoietic stem cell transplant patients |
-
2019
- 2019-07-26 CN CN201980050102.5A patent/CN112512516A/zh active Pending
- 2019-07-26 EP EP19842105.9A patent/EP3831370A4/en active Pending
- 2019-07-26 CN CN202510467128.7A patent/CN120284929A/zh active Pending
- 2019-07-26 AU AU2019311609A patent/AU2019311609B2/en active Active
- 2019-07-26 MX MX2021001039A patent/MX2021001039A/es unknown
- 2019-07-26 BR BR112021001376-8A patent/BR112021001376A2/pt unknown
- 2019-07-26 WO PCT/JP2019/029524 patent/WO2020022507A1/ja not_active Ceased
- 2019-07-26 US US17/263,440 patent/US20210283073A1/en active Pending
- 2019-07-26 JP JP2020532517A patent/JP7389486B2/ja active Active
- 2019-07-26 IL IL280451A patent/IL280451B2/en unknown
- 2019-07-26 TW TW108126590A patent/TWI899057B/zh active
- 2019-07-26 KR KR1020217002596A patent/KR102948053B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102948053B1 (ko) | 2026-04-06 |
| CN112512516A (zh) | 2021-03-16 |
| WO2020022507A1 (ja) | 2020-01-30 |
| EP3831370A4 (en) | 2022-04-27 |
| IL280451B1 (en) | 2025-06-01 |
| BR112021001376A2 (pt) | 2021-04-20 |
| US20210283073A1 (en) | 2021-09-16 |
| TWI899057B (zh) | 2025-10-01 |
| JP7389486B2 (ja) | 2023-11-30 |
| KR20210040954A (ko) | 2021-04-14 |
| IL280451B2 (en) | 2025-10-01 |
| CA3106608A1 (en) | 2020-01-30 |
| TW202011948A (zh) | 2020-04-01 |
| AU2019311609A1 (en) | 2021-02-04 |
| CN120284929A (zh) | 2025-07-11 |
| AU2019311609B2 (en) | 2024-09-26 |
| EP3831370A1 (en) | 2021-06-09 |
| IL280451A (en) | 2021-03-25 |
| JPWO2020022507A1 (ja) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015003643A (es) | Metodo para tratar el cancer. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| CL2022000195A1 (es) | Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
| MX2018005165A (es) | Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2. | |
| MX2021001039A (es) | Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas. | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| CL2018000033A1 (es) | Composición para destapar una nariz tapada que tiene actividad antiviral. | |
| CO2018004206A2 (es) | Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d” | |
| MX2018003698A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y articulos de los mismos. | |
| MX2016004285A (es) | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. | |
| UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
| NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
| MX2018013873A (es) | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| CO6761349A2 (es) | Proteína antimicrobiana | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| CL2017000636A1 (es) | Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores | |
| AR106351A1 (es) | Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento | |
| JPWO2020022507A5 (https=) | ||
| MX2017009863A (es) | Agente preventivo y/o terapeutico de enfermedad inmune. |